VC-backed Aligos Therapeutics goes public
Aligos Therapeutics, a biopharmaceutical company focused on treating viral infections and liver diseases, has raised about $150 million for its IPO after pricing its 10 million shares at $15 per share.
Aligos Therapeutics, a biopharmaceutical company focused on treating viral infections and liver diseases, has raised about $150 million for its IPO after pricing its 10 million shares at $15 per share.
Copyright PEI Media
Not for publication, email or dissemination